HOME NEWS EARNINGS RESULTS PICKS STRATEGY BLOG CONTACT SUBSCRIBE LOGIN SUBSCRIBE JOIN FREE
LOADING
Price Investing Group
← Back to Research Watchlist
TRML
Tourmaline Bio Inc
Healthcare Biotechnology Delisted · Kentucky, USA · Reports in usd
Market Cap: $1.23B
Market Cap
$1.23B
Enterprise Val
$993.2M
P/E Ratio
-13.93
P/B Ratio
4.76
Trailing PEG (1Y)
-0.43
As Of
Apr 26, 2026

Overview & Key Metrics

Reporting period: Jun 30, 2025 · Q2 2025
Book Value$259.2M
Return on Equity-30.50%
Return on Assets-29.63%
Current Ratio24.68
Debt/Equity0.00
LT Debt/Equity0.00
Revenue Per Share0.00

Income Statement

Jun 30, 2025
Revenue$0.00
Cost of Revenue$0.00
Gross Profit$0.00
R&D$19.6M
SG&A$6.3M
Operating Expenses$26.0M
Operating Income-$26.0M
Interest Expense$0.00
Tax Expense$0.00
Net Income-$23.1M
EPS (Basic)$-0.90
EPS (Diluted)$-0.90
EBIT-$23.1M
EBITDA-$23.0M
Consolidated Income-$23.1M
Non-Controlling Interests$0.00

Balance Sheet

Jun 30, 2025
Cash & Equivalents$31.7M
Accounts Receivable$0.00
Inventory$0.00
Current Assets$249.1M
LT Investments$17.2M
Property, Plant & Equipment$174.0K
Intangibles$0.00
Non-Current Assets$20.2M
Total Assets$269.3M
Accounts Payable$3.2M
Current Debt$145.0K
Current Liabilities$10.1M
LT Debt$0.00
Non-Current Liabilities$8.0K
Total Liabilities$10.1M
Total Debt$145.0K
Retained Earnings-$181.3M
Shareholder Equity$259.2M
Shares Outstanding25,688,479

Cash Flow Statement

Jun 30, 2025
Operating Cash Flow-$20.3M
Investing Cash Flow$16.3M
Financing Cash Flow$54.0K
CapEx-$7.0K
Free Cash Flow-$20.3M
Depreciation & Amort.$56.0K
Stock-Based Comp$2.5M
Acquisitions / Disposals$0.00
Investment Activity$16.3M
Debt Issued/Repaid$0.00
Equity Issued/Repaid$54.0K
Dividends Paid$0.00
Net Change in Cash-$3.9M
Data cached · Meta cache · Daily cache · Statements cache · TTL 24h